Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Front Public Health. 2022 Jul 29;10:942377. doi: 10.3389/fpubh.2022.942377. eCollection 2022.
The objective of this study was to assess the status and trends of antiviral treatment in outpatients with herpes zoster in China.
Prescription data on antiviral drugs were extracted from the database of the Hospital Prescription Analysis Program of China according to the inclusion criteria. Yearly prescriptions and costs were calculated, and trends were analyzed. The trends were further stratified by age, sex, and specific drug use. The distribution of defined daily costs (DDCs) of valaciclovir and famciclovir were analyzed, and trends in the median DDCs were identified.
A total of 132,911 prescriptions from 49 hospitals located in six major areas of China were included in the analysis. The yearly prescriptions containing antivirals increased from 8,819 in 2010 to 16,361 in 2019. The percentage of prescriptions for patients aged 65 years and above also increased (27.7% in 2010 to 31.0% in 2019), and the number of prescriptions for females was higher than those for males ( < 0.001). The average cost of antivirals per prescription decreased; thus, the yearly cost showed no increasing trend. The main prescribed antivirals were valaciclovir and famciclovir, which progressively increased in prescriptions. The use of acyclovir decreased during the study period. Prescriptions containing topical formulations, acyclovir and penciclovir, both increased. The DDCs of valaciclovir and famciclovir decreased dramatically.
The use of antivirals has increased over the decade, while the cost has not. Antiviral treatments adhere well to recent recommendations, except for the use of topical antivirals. The findings of this study may benefit the healthcare source allocation and management of herpes zoster in China.
本研究旨在评估中国门诊带状疱疹患者抗病毒治疗的现状和趋势。
根据纳入标准，从中国医院处方分析项目数据库中提取抗病毒药物的处方数据。计算年处方量和费用，并进行趋势分析。按年龄、性别和特定药物使用情况进一步分层分析趋势。分析伐昔洛韦和泛昔洛韦的限定日费用（DDC）分布，并确定中位数 DDC 的趋势。
共纳入来自中国六大地区 49 家医院的 132911 份处方。含有抗病毒药物的年处方量从 2010 年的 8819 份增加到 2019 年的 16361 份。65 岁及以上患者的处方比例也有所增加（2010 年为 27.7%，2019 年为 31.0%），女性处方数量高于男性（<0.001）。抗病毒药物每处方的平均费用有所下降；因此，年费用没有呈现上升趋势。主要的处方抗病毒药物为伐昔洛韦和泛昔洛韦，两者的处方量逐渐增加。阿昔洛韦的使用量在研究期间有所下降。含有局部制剂、阿昔洛韦和喷昔洛韦的处方均有所增加。伐昔洛韦和泛昔洛韦的 DDC 显著下降。
十年来，抗病毒药物的使用量有所增加，而费用没有增加。抗病毒治疗除了局部使用抗病毒药物外，基本符合最新建议。本研究结果可能有助于中国医疗资源的分配和带状疱疹的管理。
